Red Book Online Outbreak: Mpox

Summary

April 23, 2024:  Update from CDC on the current mpox outbreak in the Democratic Republic of Congo. 

Since the start of the current global outbreak that started in May 2022, there have been 32,063 confirmed cases of mpox (formerly known as monkeypox) and 58 deaths in the US. As of January 10, 2024, CDC is no longer updating the mpox outbreak US case count. There has not been a marked change in weekly or monthly national case counts during the last 6 months. The majority of US cases continue to be in people who are not vaccinated or who have only received one dose of JYNNEOS. This outbreak is part of a larger global outbreak (99,518 cases) that is occurring in 122 locations (countries, territories, and areas) and is caused by clade II of mpox. The risk of children getting infected with mpox virus is low. Of the total 32,063 US mpox cases, 64 cases have been reported in children 0-15 years old and 699 cases have been reported in adolescents/young adults 16- 20 years old in the US. The proportion of cases by race and ethnicity that have been reported are: Black or African American (32%), Hispanic or Latino (31%), or White (29%). More information on mpox case demographics can be found here.  

Clinical Guidance

• Presentation: Mpox should be suspected in patients presenting with a rash consistent with mpox,  especially (but not solely) in patients with exposure to someone known to have or suspected to have mpox. Clinical judgement and consultation with an infectious disease specialist and/or your local public health department is important in determining who needs testing, as the overwhelming majority of children who present with a rash will have an alternative etiology.
  • The rash associated with mpox produces macules that progress to papules, vesicles, and then pustules that are deep-seated, firm or hard, and well-circumscribed; the lesions may umbilicate or become confluent and progress over time to scabs. Rash may spread to other parts of the body. In classic mpox, lesions on a particular body part are in the same stage. This has not always been the case in the current outbreak, with lesions in varying stages of progression being seen in many patients in the US currently, and lesions may be few in number, and limited to one area.
  • Presenting symptoms typically include fever, chills, malaise, sore throat, headache, and new lymphadenopathy, followed by the distinctive rash. In the current outbreak, onset of perianal or genital lesions in the absence of fever or other systemic symptoms or concurrently with systemic symptoms also has been reported. Other symptoms include difficulty swallowing or cough when oropharyngeal lesions are present. Ocular lesions may present with eyelid swelling or crusting.
  • The rash associated with mpox can be confused with other diseases that are more commonly encountered in clinical practice (eg, syphilis, herpes simplex virus [HSV], chancroid, varicella zoster, and molluscum contagiosum). In addition, some patients have been coinfected with syphilis or HSV and mpox. A high index of suspicion for mpox is warranted when evaluating patients with a new onset of clinically compatible rash, who present with lesions in the genital/perianal area or for patients who had contact with a suspected or known case of mpox.
  • Pediatricians can review the case definition of mpox for more information.
• Diagnosis: If a patient is suspected of having mpox, the clinician should contact the health department to discuss testing or may use one of the commercial laboratories discussed below. Some academic centers also have the capacity to test for mpox virus. Testing at a designated laboratory response network (LRN) laboratory or a commercial laboratory is generally done with an orthopoxvirus PCR test. A positive orthopoxvirus PCR in a patient suspected of mpox is sufficient to consider the patient as having mpox, and public health officials will initiate an investigation and provide recommendations. Clinicians may order testing at commercial labs without prior authorization from public health authorities. Testing is performed on skin lesion material (dry swab, swab placed in viral culture media, or crusts) or mucosal lesion material. Requirements for specimen collection may differ by laboratory and clinicians should confirm requirements before obtaining a sample. Unroofing or aspiration of lesions during specimen collection or using sharp instruments for mpox lesion testing is not necessary or recommended due to the risk for sharps injury. Testing on blood or other body fluids is not available. For information on testing specimens that will be sent to an LRN laboratory see Preparation and Collection of Specimens | mpox | Poxvirus | CDC. Clinicians should be aware that false positive tests have occurred in patients (including children) who were at low risk, without a known epidemiological link, and who had a high cycle threshold value; for more information see MMWR.
• Complications: Patients with mpox can develop a variety of complications, including encephalitis, encephalomyelitis, pneumonia, sepsis, hemorrhagic disease, myocarditis, pericarditis, other conditions requiring hospitalization, blindness (secondary to ocular infection), and bacterial skin infections. If the patient is pregnant, there may be complications, including preterm delivery, fetal death, or congenital disease; data are very limited. For more information: Monitoring People Who Have Been Exposed | mpox | Poxvirus | CDC
• Precautions: Mpox spreads person to person primarily through contact with infectious rashes, prolonged face-to-face contact, or items that previously touched the infectious rash or body fluids. Standard precautions should be applied for all patient care, including for patients with suspected mpox. If a patient seeking care is suspected to have mpox, infection prevention and control personnel should be notified immediately. In the inpatient setting, persons with suspected or confirmed mpox should be placed in a single patient room with a dedicated bathroom. Special air handling for mpox is not required except during aerosol-generating procedures (although airborne isolation is required for some infections associated with rash, such as varicella or measles). Intubation, extubation, and any procedure likely to spread oral secretions should be performed in a negative pressure isolation room. In ambulatory healthcare settings, the lesions of patients with suspected or confirmed mpox should be covered and patients who are at least 2 years of age should be masked. Patients should be put in an exam room promptly. In both inpatient and ambulatory settings, the PPE used by healthcare personnel who enter the patient’s room should include a gown, gloves, eye protection (ie, goggles or face shield), and a NIOSH-approved particulate respirator equipped with N95 filters or higher. For more information: How it Spreads | mpox | Poxvirus | CDC.
• Standard cleaning and disinfection procedures should be performed using an EPA-registered hospital-grade disinfectant with an emerging viral pathogen claim. Products with Emerging Viral Pathogens claims may be found on EPA’s List Q. Follow the manufacturer’s directions for concentration and contact time. Activities that could resuspend dried material from lesions (eg, use of portable fans, dry dusting, sweeping, or vacuuming) should be avoided. Waste contaminated with mpox virus associated with this outbreak in the United States, clade II of mpox virus, including disposable PPE, should be managed as UN3291 Regulated Medical Waste (RMW) in the same manner as other potentially infectious medical waste (eg, soiled dressings, contaminated sharps). Waste from individuals who have risk factors for clade I of mpox (eg, history of travel to the Democratic Republic of the Congo, the Republic of Congo, the Central African Republic, Cameroon, or Gabon in the prior 21 days) must be managed as Category A waste pending clade confirmation.
• Risk Mitigation: Children and adolescents with mpox who do not require hospitalization should be isolated at home. Infected persons should avoid contact with uninfected people and pets until the rash has resolved, the scabs have fallen off, and a fresh layer of intact skin has formed. When possible, the number of caregivers should be limited to one person who has been educated about infection prevention strategies. Caregivers should wear a respirator or well-fitting face mask, cover areas of broken skin with bandages and clothing to the extent possible and avoid direct skin-to-skin contact with the rash. During interactions with uninfected caregivers, children over 2 years of age with mpox should wear well-fitting source control (eg, a medical mask) when possible. Caregivers assisting with changing bandages or clothes covering the rash should wear gloves to avoid infection, dispose of gloves after use and perform handwashing.
  • Decisions regarding discontinuation of isolation precautions at a healthcare facility and at home should be made in consultation with the local or state health department. For patients with mpox, isolation precautions are recommended to continue until all lesions have resolved, the scabs have fallen off, and a fresh layer of intact skin has formed. For questions about home isolation for individual patients and circumstances, discussion with local or state health departments is recommended. For more information: Isolation and Infection Control: Home | mpox | Poxvirus | CDC  
    • CDC recommends that people whose jobs (clinical or research laboratories and certain healthcare and public health team members) may expose them to orthopoxviruses, such as mpox, get vaccinated with JYNNEOS or ACAM2000 to protect them from an orthopoxvirus infection. At this point, vaccination is not recommended for most healthcare providers.
    • ACIP recommends vaccination with the 2-dose JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox. Persons at risk:
      • Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
        • A new diagnosis of ≥1 sexually transmitted disease
        • More than one sex partner
        • Sex at a commercial sex venue
        • Sex in association with a large public event in a geographic area where mpox transmission is occurring
      • Sexual partners of persons with the risks described in above
      • Persons who anticipate experiencing any of the above
    • Public health officials may recommend vaccine for contacts of mpox cases, especially those that are found to be at high risk. Healthcare providers who have unprotected, high risk contact with patients with mpox may be eligible for post-exposure prophylaxis in consultation with public health authorities.
    • The standard regimen for JYNNEOS vaccine is a 0.5 mL dose administered subcutaneously followed by a second dose 28 days later.
    • JYNNEOS vaccine may be recommended for and given to children <18 years of age for post-exposure prophylaxis under an emergency use authorization protocol. Clinicians should discuss use of vaccine in a child as post-exposure prophylaxis with the state or local health department. Only subcutaneous administration of JYNNEOS vaccine is authorized for children <18 years of age.
    • Vaccinia immune globulin is available through an IND protocol for the potential prevention of mpox, but its effectiveness is unknown. Vaccinia immune globulin is an alternative to vaccine for post-exposure prophylaxis, especially in children <6 months of age.
    • Tecovirimat may be considered for post-exposure prophylaxis when vaccine is contraindicated; its effectiveness is unknown.
• Treatment: Mpox is typically a self-limiting condition. Some patients are at higher risk for severe disease and should be considered for treatment on a case-by-case basis, including immunocompromised patients, pregnant or breastfeeding persons, children under 1 year, and those with atopic dermatitis or another condition that affects skin integrity. In addition, those with complicated or severe disease, or with lesions in the areas that might result in severe sequelae, including scarring and strictures (eye, mouth, genitals, or anus/rectum), should be considered for treatment. For more information: Treatment Information for Healthcare Professionals |mpox |CDC . Consultation with an infectious disease expert is recommended. State or local public health officials can facilitate consultation access to antiviral therapy. There is no treatment approved specifically for mpox virus infections. However, antivirals developed for use in patients with smallpox may prove beneficial against mpox. The following medical countermeasures are available from the Strategic National Stockpile (SNS) as options for the treatment of mpox:
  
  • Tecovirimat (also known as TPOXX, ST-246), developed for treatment of smallpox, is  being used as a first-line treatment  for patients weighing 3 kg or more through an expanded access protocol for mpox (see package insert: label [fda.gov]). Oral dosing is most feasible for children who weigh at least 13 kg and can take capsules, or the contents of a capsule mixed with soft food. The drug should be administered with a fatty meal to increase absorption. Because accurate oral dosing of children <13 kg is challenging, intravenous therapy may be considered when tecovirimat is indicated. Renal immaturity in patients <2 years of age may result in higher exposure to hydroxypropyl-β-cyclodextrin, an ingredient in intravenous tecovirimat. In animal studies, hydroxypropyl-β-cyclodextrin demonstrated the potential for nephrotoxicity at high levels. At least weekly monitoring of renal function is indicated in children and adolescents receiving intravenous tecovirimat. Tecovirimat has not been studied in children to date. Evidence of efficacy in the treatment of mpox is based largely on animal studies. The potential risks and benefits should be considered prior to initiating therapy. Resistance to tecovirimat has been reported.
  • CDC has an expanded access protocol for Vaccinia Immune Globulin Intravenous (VIGIV) in the case of a mpox outbreak (download [fda.gov]). Effectiveness is unknown.
  • The use of antiviral medications cidofovir and brincidofovir may also be considered, but these should be used with caution due to potential toxicity and very limited experience with mpox.
    • Cidofovir (also known as Vistide), which is approved for CMV retinitis, has an expanded access protocol for treatment of mpox (FDA VISTIDE cidofir injection).
    • Brincidofovir (also known as CMX001 or Tembexa), which is approved for smallpox treatment (FDA TEMBEXA brincidofovir) is now available in the SNS through an expanded access investigational new drug protocol for mpox by CDC.

• Reporting and assistance: Clinicians should report cases to state or local health departments (State Contacts) as soon as mpox is suspected. If you have a patient that meets the probable or confirmed case definition, the health department will notify CDC. For more information: Case Reporting Recommendations for Health Departments | mpox | Poxvirus | CDC

See Special Populations for the management of newborns infected with mpox virus.

Resources

• For more information see the Red Book chapter: Mpox
• CDC Health Advisory Notice from December 7, 2023: HAN Archive – 00501
• Frantzis I, Ungar SP, Soma VL, et al. Mpox in Children: 3 Cases. Pediatrics. 2024;153(2): e2022061047